Case Report: Anti-PD-1 therapy as a catalyst for the rapid transformation of a hepatic nodule into HCC: a “soil and seed” paradox in metachronous triple primary malignancies? - Takeaways - MDSpire

Case Report: Anti-PD-1 therapy as a catalyst for the rapid transformation of a hepatic nodule into HCC: a “soil and seed” paradox in metachronous triple primary malignancies?

  • By

  • Xian Yang

  • Dehua Kong

  • Boan Lai

  • Chuan Zhang

  • Na Li

  • May 1, 2026

  • 0 min

Share

  • 1

    A 68-year-old male with chronic HBV developed metachronous triple primary malignancies during PD-1 inhibitor therapy.

  • 2

    While on sintilimab for gastric adenocarcinoma, a stable hepatic nodule rapidly transformed into hepatocellular carcinoma.

  • 3

    The case suggests that immune checkpoint inhibitors may disrupt local immune tolerance, accelerating dormant neoplastic processes.

  • 4

    Despite effective treatment of lung and gastric cancers, the emergence of HCC highlights the complex effects of ICIs.

  • 5

    This case underscores the need for rigorous liver assessments and monitoring in high-risk patients receiving immunotherapy.

Original Source(s)

Case Report: Anti-PD-1 therapy as a catalyst for the rapid transformation of a hepatic nodule into HCC: a “soil and seed” paradox in metachronous triple primary malignancies?

  • by Xian Yang, Dehua Kong, Boan Lai, Chuan Zhang, Na Li

  • May 1, 2026

Related Content

Potential targets for boron transport in boron neutron capture therapy

Synthetic short RNA in cancer

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma